Chao, Jiashuo
Wang, Shanshan
Wang, Hao
Zhang, Nan
Wang, Yunchao
Yang, Xu
Zhu, Chengpei
Ning, Cong
Zhang, Xinmu
Xue, Jingnan
Zhang, Longhao
Piao, Mingjian
Wang, Mingming
Yang, Xiaobo
Lu, Ling
Zhao, Haitao
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers
https://doi.org/10.1136/jitc-2020-001942
Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
https://doi.org/10.1007/s00262-023-03523-2
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinoma
https://doi.org/10.1136/jitc-2023-008686
Funding for this research was provided by:
CSCO-Hengrui Cancer Research Fund (Y-HR2019-0239, Y-HR2020QN-0414)
CAMS Innovation Fund for Medical Sciences (2019-I2M-5-035, 2021-I2M-1-061, 2022-I2M-C&T-A-003)
National High Level Hospital Clinical Research Funding (2022-PUMCH-B-128)
CSCO-MSD Cancer Research Fund (Y-MSDZD2021-0213)
National Ten-thousand Talent Program
Article History
Received: 30 June 2023
Accepted: 10 August 2023
First Online: 3 October 2023
Declarations
:
: All authors declare that they have no conflict of interest.
: The study was approved by the Ethics Committee of Peking Union Medical College Hospital (No. JS-1391), and was conducted in accordance with the Declaration of Helsinki. Informed consent was obtained from all patients.